目的:opiorphin是从人类唾液中分离出的一种五肽,可以抑制化学诱导的炎症和急性身体疼痛引起的疼痛。口腔灼烧综合征(BMS)是一种口腔灼烧感的慢性病,无法确定潜在的牙科或医疗原因。我们旨在测量BMS患者的整个未刺激(UWS)和刺激(SWS)唾液中的opiorphin水平。
方法:最初开发和验证的LC-MS/MS方法用于阿片样蛋白定量。样本来自29名BMS患者和29名年龄和性别匹配的对照。
结果:BMS组UWS和SWS中opiorphin的平均浓度为8.13±6.45和5.82±3.59ng/ml,分别。BMS患者的Opiorphin\'UWS显着升高,与对照组相比(t=2.5898;p=0.0122)。SWSopiorphin水平较高,但并不重要,BMS患者比对照组。
结论:我们的结果表明,BMS中唾液阿片类药物含量较高可能是慢性疼痛的结果,但我们不能排除它们是可能与BMS相关的情绪和行为失衡的结果。据我们所知,这是在疼痛障碍中测量opiorphin的第一篇原始文章。
结论:opiorphin可能是慢性疼痛的可测量生物标志物,这可以帮助客观化,否则完全是主观体验。阿片类药物的增加可以作为疼痛状况的普遍客观指标。由于opiorphin也可能反映BMS发生的情感和社会关系失衡,它也可以代表BMS的生物标志物。关于阿片样蛋白参与疼痛通路的知识可能有助于开发新的BMS临床诊断方法。
OBJECTIVE: Opiorphin is a pentapeptide isolated from human saliva that suppresses pain from chemically induced inflammation and acute physical pain. Burning mouth syndrome (BMS) is a chronic condition of a burning sensation in the mouth, where no underlying dental or medical cause can be identified. We aimed to measure the level of opiorphin in whole unstimulated (UWS) and stimulated (SWS) saliva of patients with BMS.
METHODS: Originally developed and validated LC-MS/MS method was used for opiorphin quantification. Samples were obtained from 29 BMS patients and 29 age- and sex-matched controls.
RESULTS: The average concentration of opiorphin in UWS and SWS in the BMS group was 8.13 ± 6.45 and 5.82 ± 3.59 ng/ml, respectively. Opiorphin in BMS patients\' UWS was significantly higher, compared to the control group (t = 2.5898; p = 0.0122). SWS opiorphin levels were higher, but not significantly, in BMS patients than in controls.
CONCLUSIONS: Our results indicate that higher quantities of salivary opiorphin in BMS may be a consequence of chronic pain, but we cannot exclude that they occur as a result of emotional and behavioral imbalances possibly associated with BMS. To our knowledge, this is the first original article measuring opiorphin in a pain disorder.
CONCLUSIONS: Opiorphin may be a measurable biomarker for chronic pain, which could help in objectifying otherwise exclusively a subjective experience. Increased opiorphin could serve as a universal objective indicator of painful conditions. Since opiorphin may also reflect emotional and socio-relational imbalances occurring with BMS, it could as well represent a biomarker for BMS. Knowledge on opiorphin\'s involvement in pain pathways could contribute to developing new clinical diagnostic methods for BMS.